Neurocrine Biosciences, Inc.
corporate_fare Company Profile
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 22 items for NBIX at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-03, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 14 rated 8 or above. Recent SEC coverage for NBIX spans 10-Q, 8-K, DEFA14A, DEF 14A.
Recent high-impact activity:
- Neurocrine Jumps 15% on Third Straight Double Beat and Second Ingrezza Guidance Hike
- Neurocrine Posts $3.29 Q3 Adjusted EPS as Revenue Jumps 41%
- Neurocrine 10-Q: Q3 Revenue $1.12B, Net Income $206.5M; New VYKAT XR Generic Suit Filed
- Neurocrine Q3 Revenue Tops $1.1B, INGREZZA Guidance Raised to $2.9-$2.925B
- FDA Clears Phase 2 Trial for Neurocrine's Alzheimer's Drug NBI-1117567
Financial Snapshot
Short Interest & Short Volume
5.40 days to coverFINRA reported short interest of 5,900,825 shares in NBIX as of the October 30, 2026 settlement, a 8.5% decrease from the prior period — about 5.4 days to cover at its recent average daily volume. On November 19, 2026, 61.7% of NBIX volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.